Information Provided By: 
Fly News Breaks for March 7, 2017
ESRX
Mar 7, 2017 | 07:51 EDT
Leerink analyst David Larsen is "incrementally more positive" on Express Scripts after speaking with management about a variety of issues. The analyst believes that under the leadership of new CEO Tim Wentworth, Express Scripts is taking a more aggressive and creative approach to the market, thinks PBMs are on the right side of the ongoing drug-pricing saga, and notes that the stock has pulled in about 25% from its 2-year highs. He reiterates a Market Perform and $75 price target on the shares.
News For ESRX From the Last 2 Days
There are no results for your query ESRX
